Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma

[PR Newswire] – CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ — Epizyme, Inc., (EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication more

View todays social media effects on EPZM

View the latest stocks trending across Twitter. Click to view dashboard

See who Epizyme is hiring next, click here to view